Afatinib Active Not Recruiting Phase 2 Trials for Lung Cancer Non-Small Cell Cancer (NSCLC) Treatment

IndicationsStatusPurposePhase
Active Not RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT03157089Testing Afatinib in Combination With Pembrolizumab in Patients With Squamous Cell Carcinoma of the Lung
NCT03727724Afatinib and Cetuximab in Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Positive Non-small-cell Lung Cancer
NCT01156545BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC
NCT01746251Adjuvant Afatinib in Stage I-III NSCLC With EGFR Mutation